New standards in hypertension and cardiovascular risk management: focus on telmisartan

References

• WeberMAInterrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertensionAm J Hypertens199912189S194S10619571
   PubMed Web of Science ®Google Scholar
• KakutaHSudohKSasamataMTelmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockersInt J Clin Pharmacol Res200525414615864875
   PubMedGoogle Scholar
• WienenWHauelNvan MeelJCPharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277Br J Pharmacol19931102452528220885
   PubMed Web of Science ®Google Scholar
• WienenWEntzerothMvan MeelJCAA review on telmisartan: a novel, long-acting angiotensin II-receptor antagonistCardiovasc Drug Rev200018127156
   Google Scholar
• StangierJSuCAPFRothWPharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patientsJ Int Med Res20002814916711014323
   PubMed Web of Science ®Google Scholar
• BrunnerHRThe new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewJ Hum Hypertens200216Suppl 2S13S1611967728
   PubMedGoogle Scholar
• BurnierMBrunnerHRAngiotensin II receptor antagonistsLancet200035563764510696996
   PubMed Web of Science ®Google Scholar
• EbnerTHeinzelGProxADisposition and chemical stability of telmisartan 1-O-acylglucuronideDrug Metab Dispos1999271143114910497140
   PubMed Web of Science ®Google Scholar
• StangierJSuCAPFvan HeiningenPNMInhibitory effect of telmisartan on the blood pressure response to angiotensin II challengeJ Cardiovasc Pharmacol20013867268511602814
   PubMed Web of Science ®Google Scholar
• PershadsinghHAKurtzTWInsulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular diseaseDiabetes Care200427101515047668
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activityHypertension200443993100215007034
   PubMed Web of Science ®Google Scholar
• FujimotoMMasuzakiHTanakaTAn angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytesFEBS Lett200457649249715498586
   PubMed Web of Science ®Google Scholar
• ClasenRSchuppMForyst-LudwigAPPARγ-activating angiotensin type-1 receptor blockers induce adiponectinHypertension20054613714315939809
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor-γ modulators with angiotensin receptor blocking activityDiabetes2005543442345216306360
   PubMed Web of Science ®Google Scholar
• BrodyRPelegEGrossmanEProduction and secretion of adiponectin from 3T3-L1 adipocytes: comparison of antihypertensive drugsAm J Hypertens2009221126112919730415
   PubMed Web of Science ®Google Scholar
• NakamuraTKawachiKSaitoYEffects of ARB or ACE-inhibitor administration on plasma levels of adlosterone and adiponectin in hypertensionInt Heart J20095050151219609054
   PubMed Web of Science ®Google Scholar
• KappertKTsuprykovOKaufmannJChronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPAR {gamma} activationHypertension20095473874319687349
   PubMed Web of Science ®Google Scholar
• JankeJSchuppMEngeliSAngiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activationJ Hypertens2006241809181616915030
   PubMed Web of Science ®Google Scholar
• MarshallTGLeeREMarshallFECommon angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2bTheor Biol Med Model2006118617421746
   Google Scholar
• CostaFVTelmisartan: standing out in a crowded contest?High Blood Press Cardiovasc Prev2006138594
   Google Scholar
• RedónJRoca-CusachsAMora-MaciaJUncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoringBlood Press Monit2002711111612048428
   PubMed Web of Science ®Google Scholar
• IskedjianMEinarsonTRMacKeiganLDRelationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysisClin Ther20022430231611911560
   PubMed Web of Science ®Google Scholar
• MullerJEStonePHTuriZGCircadian variation in the frequency of onset of acute myocardial infarctionN Engl J Med1985313131513222865677
   PubMed Web of Science ®Google Scholar
• MarlerJRPriceTRClarkGLMorning increase in onset of ischemic strokeStroke1989204734762648651
   PubMed Web of Science ®Google Scholar
• ElliottWJCircadian variation in the timing of stroke onset – a meta-analysisStroke1998299929969596248
   PubMed Web of Science ®Google Scholar
• Millar-CraigMWBishopCNRafteryEBCircadian variation of blood-pressureLancet1978i79579785815
   PubMedGoogle Scholar
• SternNSowersJRMcGintyDCircadian rhythm of plasma renin activity in older normal and essential hypertensive men: relation with inactive renin, aldosterone, cortisol and REM sleepJ Hypertens198645435503540117
   PubMed Web of Science ®Google Scholar
• CasigliaEPalatiniPColangeliG24 h rhythm of blood pressure and forearm peripheral resistance in normotensive and hypertensive subjects confined to bedJ Hypertens199614475212013494
   PubMed Web of Science ®Google Scholar
• LearyACStruthersADDonnanPTThe morning surge in blood pressure and heart rate is dependent on levels of physical activity after wakingJ Hypertens20022086587012011646
   PubMed Web of Science ®Google Scholar
• WhiteWBGilesTBakrisGLMeasuring the efficacy of anti-hypertensive therapy by ambulatory blood pressure monitoring in the primary care settingAm Heart J2006a15117618416368314
   PubMed Web of Science ®Google Scholar
• PhillipsRAWeinbergJMHypertension 2005: an evidence-based approach to diagnosis and treatment – an American perspectiveExpert Rev Cardiovasc Ther2005369170416076279
   PubMedGoogle Scholar
• WhiteWBWeberMADavidaiGAmbulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 TrialBlood Press Monit20051015716315923818
   PubMed Web of Science ®Google Scholar
• NishimuraTHashimotoJOhkuboTEfficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurementsClin Exp Hypertens20052747748916081340
   PubMed Web of Science ®Google Scholar
• WhiteWBLacourcièreYDavidaiGEffects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning periodAm J Hypertens20041734735315062889
   PubMed Web of Science ®Google Scholar
• LacourcièreYKrzesinskiJMWhiteWBSustained antihypertensive activity of telmisartan compared with valsartanBlood Press Monit2004920321015311147
   PubMed Web of Science ®Google Scholar
• MallionJMSichéJPLacourcièreYThe Telmisartan Blood Pressure Monitoring GroupABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertensionJ Hum Hypertens19991365766410516734
   PubMed Web of Science ®Google Scholar
• SmithDHCramerMJNeutelJMComparison of telmisartan versus losartan: meta-analysis of titration-to-response studiesBlood Press Monit2003811111712900588
   PubMed Web of Science ®Google Scholar
• DingPYChuKMChiangHTA double-blind ambulatory blood pressure monitoring study of the efficacy and tolerability of once-daily telmisartan 40 mg in comparison with losartan 50 mg in the treatment of mild-to-moderate hypertension in Taiwanese patientsInt J Clin Pract Suppl200458162215617454
   PubMedGoogle Scholar
• DerosaGRagonesiPDMugelliniAEffects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month studyHypertens Res20042745746415302981
   PubMed Web of Science ®Google Scholar
• NakayamaSWatadaHMitaTComparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertensionHypertens Res20083171318360012
   PubMed Web of Science ®Google Scholar
• SasakiTNodaYYasuokaYComparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndromeHypertens Res20083192192918712048
   PubMed Web of Science ®Google Scholar
• WilliamsBGossePLoweLThe prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)J Hypertens20062419320016331118
   PubMed Web of Science ®Google Scholar
• LacourcièreYNeutelJMDavidaiGA multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoringAm J Hypertens20061910411216461201
   PubMed Web of Science ®Google Scholar
• GossePNeutelJMSchumacherHThe effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trialsBlood Press Monit20071214114717496463
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet20023601903191312493255
   PubMed Web of Science ®Google Scholar
• NalbantgilINalbantgilSÖzerkanFThe efficacy of telmisartan compared with perindopril in patients with mild-to-moderate hypertensionInt J Clin Pract2004585054
   Web of Science ®Google Scholar
• RagotSEzzaherAMeunierAComparison of trough effect of telmisartan vs perindopril using self blood pressure measurement: EVERESTE studyJ Hum Hypertens20021686587312522468
   PubMed Web of Science ®Google Scholar
• StergiouGSEfstathiouSPRoussiasLGBlood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared with lisinoprilJ Cardiovasc Pharmacol20034249149614508234
   PubMed Web of Science ®Google Scholar
• NeutelJMFrishmanWHOparilSComparison of telmisartan with lisinopril in patients with mild-to-moderate hypertensionAm J Ther1999616116610423659
   PubMedGoogle Scholar
• ONTARGET InvestigatorsYusufSTeoKKTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med20083581547155918378520
   PubMed Web of Science ®Google Scholar
• FreytagFSchellingAMeinickeTComparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild-to-moderate hypertension: a randomized, multicenter studyClin Ther20012310812311219471
   PubMed Web of Science ®Google Scholar
• AlcocerLFernandez-BonettiPCamposEClinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertensionInt J Clin Pract Suppl200458353915617457
   PubMedGoogle Scholar
• GalzeranoDTammaroPdel ViscovoLThree-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal studyAm J Hypertens2005181563156916364826
   PubMed Web of Science ®Google Scholar
• LacourcièreYLenisJOrchardRA comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipineBlood Press Monit1998329530210212369
   PubMedGoogle Scholar
• DerosaGCiceroAFGBertoneGComparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: A 12-month, randomized, double-blind studyClin Ther2004261228123615476904
   PubMed Web of Science ®Google Scholar
• McGillJBReillyPATelmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trialClin Ther20012383385011440284
   PubMed Web of Science ®Google Scholar
• GalzeranoDTammaroPCercielloAFreehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre studyJ Hum Hypertens200418535914688811
   PubMed Web of Science ®Google Scholar
• ManolisAJReidJLde ZeeuwDAngiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placeboJ Hypertens2004221033103715097245
   PubMed Web of Science ®Google Scholar
• LacourcièreYNeutelJMSchumacherHComparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: Pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trialsClin Ther2005271795180516368450
   PubMed Web of Science ®Google Scholar
• WhiteWBPunziHAMurwinDEffects of the angiotensin II receptor blockers telmisartan vs valsartan in combination with hydrochlorothiazide 25 mg once daily for the treatment of hypertensionJ Clin Hypertens (Greenwich)2006862663316957424
   PubMedGoogle Scholar
• WhiteWBMurwinDChrysantSGEffects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trialBlood Press Monit200813212718199920
   PubMed Web of Science ®Google Scholar
• FogariRZoppiAMugelliniAEffectiveness of hydrochlorothiazide in combination with telmisartan and olmesartan in adults with moderate hypertension not controlled with monotherapy: a prospective, randomized, open-label, blinded end point (PROBE), parallel-arm studyCurr Ther Res200869115
   PubMed Web of Science ®Google Scholar
• LacourcièreYTytusRO’KeefeDEfficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapyJ Hum Hypertens20011576377011687919
   PubMed Web of Science ®Google Scholar
• SharmaADavidsonJKovalSTelmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH studyCardiovasc Diabetol200762817910747
   PubMed Web of Science ®Google Scholar
• NeldamSEdwardsCTelmisartan plus HCTZ vs amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring studyAm J Geriatr Cardiol20061615116016687967
   PubMedGoogle Scholar
• SchumacherHManciaGThe safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studiesBlood Press Suppl20081324018705533
   PubMedGoogle Scholar
• LittlejohnTMajulCOlveraRResults of treatment with telmisartan-amlodipine in hypertensive patientsJ Clin Hypertens20091117
   Web of Science ®Google Scholar
• LittlejohnTMajulCOlveraREffect of telmisartan addition to amlodipine on reduction of incidence of peripheral oedema: safety analysis from a factorial study in hypertensive patientsJ Hypertens200826Suppl 1S460
   Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet2002359995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGfor the Valsartan Heart Failure Trial InvestigatorsA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med3451667167511759645
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet200336275976613678868
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med20033491893190614610160
   PubMed Web of Science ®Google Scholar
• PortaluppiFBoariBManfrediniROxidative stress in essential hypertensionCurr Pharm Des2004101695169815134566
   PubMed Web of Science ®Google Scholar
• TakayaTKawashimaSShinoharaMAngiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient miceAtherosclerosis200618640241016157344
   PubMed Web of Science ®Google Scholar
• TakaiSKirimuraKJinDSignificance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodelingHypertens Res20052859360016335888
   PubMed Web of Science ®Google Scholar
• ThornalleyPJCell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEsCell Mol Biol199844101310239846883
   PubMed Web of Science ®Google Scholar
• NakamuraKYamagishiSNakamuraYTelmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertensionMicrovasc Res20057013714116271939
   PubMed Web of Science ®Google Scholar
• YamagishiSTakeuchiMMatsuiTAngiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpressionFEBS Lett20055794265427016051229
   PubMed Web of Science ®Google Scholar
• EyriesMCollinsTKhachigianLMModulation of growth factor gene expression in vascular cells by oxidative stressEndothelium20041113313915370072
   PubMed Web of Science ®Google Scholar
• AmanoSYamagishiSInagakiYAngiotensin II stimulates platelet-derived growth factor-B gene expression in cultured retinal pericytes through intracellular reactive oxygen species generationInt J Tissue React200325515514518593
   PubMedGoogle Scholar
• YamagishiSAmanoSInagakiYAngiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generationDrugs Exp Clin Res200329758012951837
   PubMedGoogle Scholar
• SchmiederREDellesCMimranAImpact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetesDiabetes Care2007301351135617337492
   PubMed Web of Science ®Google Scholar
• SymeonidesPKoulourisSTriantafyllouKFavourable pleiotropic effects of ramipril and telmisartan on vascular endothelium of diabetics [abstract]J Am Coll Cardiol200545Suppl A428A
   Google Scholar
• LaurentSBoutouyriePAsmarRAortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patientsHypertension2001371236124111358934
   PubMed Web of Science ®Google Scholar
• WilkinsonIBMacCallumHHupperetzPCChanges in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in manJ Physiol200153054155011158283
   PubMed Web of Science ®Google Scholar
• VingerhoedtNMGillesRHowesJBHemodynamic and pulse wave responses to intravenous infusions of angiotensin II during chronic telmisartan therapy in normal volunteersJ Renin Angiotensin Aldosterone Syst2003424424814689372
   PubMed Web of Science ®Google Scholar
• AsmarRGossePTopouchianJEffects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertensionJ Renin Angiotensin Aldosterone Syst2003317618012563568
   PubMed Web of Science ®Google Scholar
• UchidaHNakamuraYKaiharaMPractical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertensionHypertens Res20042754555015492473
   PubMed Web of Science ®Google Scholar
• HaffnerSMRisk constellations in patients with metabolic syndrome: epidemiology, diagnosis and treatment patternsAm J Med2006119Suppl 5AS3S916563945
   PubMedGoogle Scholar
• MiuraYYamamotoNTsunekawaSReplacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequencesDiabetes Care20052875775815735228
   PubMed Web of Science ®Google Scholar
• MichelMCBohnerHKösterJSafety of telmisartan in patients with arterial hypertension. An open-label observational studyDrug Saf20042733534415061687
   PubMed Web of Science ®Google Scholar
• HonjoSNichiYWadaYPossible beneficial effect of telmisartan on glycemic control in diabetic subjectsDiabetes Care20052849815677828
   PubMed Web of Science ®Google Scholar
• NegroRHassanHThe effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patientsJ Renin Angiotensin Aldosterone Syst2006a724324617318795
   PubMed Web of Science ®Google Scholar
• NagelJMTietzABGokeBThe effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjectsMetabolism2006551149115416919531
   PubMed Web of Science ®Google Scholar
• BenndorfRARudolphTAppelDTelmisartan improves insulin sensitivity in nondiabetic patients with essential hypertensionMetabolism2006551159116416919533
   PubMed Web of Science ®Google Scholar
• VitaleCMercuroGCastiglioniCMetabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndromeCardiovasc Diabetol20054615892894
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med20043511952196115516696
   PubMed Web of Science ®Google Scholar
• LeveyASAdlerSCaggiulaAWEffects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease StudyAm J Kidney Dis1996276526638629624
   PubMed Web of Science ®Google Scholar
• LacourcièreYBelangerAGodinCLong-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathyKidney Int20005876276910916100
   PubMed Web of Science ®Google Scholar
• ParvingHHAndersenSJacobsenPAngiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end pointsSemin Nephrol20042414715715017527
   PubMed Web of Science ®Google Scholar
• VogtLNavisGKösterJThe angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trialJ Hypertens2005232055206116208149
   PubMed Web of Science ®Google Scholar
• RedónJLuque-OteroMMartellNRenin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patientsPhamacogenomics J200551420
   PubMed Web of Science ®Google Scholar
• HannedoucheTChanardJBaumelouBEvaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertensionJ Renin Angiotensin Aldosterone Syst2001224625411881131
   PubMed Web of Science ®Google Scholar
• CupistiARizzaGMD’AlessandroCEffect of telmisartan on the proteinuria and circadian blood pressure profile in chronic renal patientsBiomed Pharmacother20035716917212818479
   PubMed Web of Science ®Google Scholar
• SengulAMAltuntasYKurkluABeneficial effect of lisinopril plus telmisartan patients with type 2 diabetes, microalbuminuria and hypertensionDiabetes Res Clin Pract20067121021916112244
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTPrevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetesDiabetes Care2007301577157817389334
   PubMed Web of Science ®Google Scholar
• BakrisGBurgessEWeirMTelmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyKidney Int20087436436918496508
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSBögerRHWannerCAntiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant2008233174318318450829
   PubMed Web of Science ®Google Scholar
• KannelWBLeft ventricular hypertrophy as a risk factor in arterial hypertensionEur Heart J199213Suppl D82881396865
   PubMed Web of Science ®Google Scholar
• DevereuxRBWachtellKGerdtsEPrognostic significance of left ventricular mass change during treatment of hypertensionJAMA20042922350235615547162
   PubMed Web of Science ®Google Scholar
• BouzegrhaneFThibaultGIs angiotensin II a proliferative factor of cardiac fibroblasts?Cardiovasc Res20025330431211827680
   PubMed Web of Science ®Google Scholar
• IvanovaOVFomichevaOASergakovaLMAngiotensin II receptor blocker telmisartan: Effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertensionJ Int Med Res200533Suppl 121A29A15651713
   PubMedGoogle Scholar
• PetrovicJPetrovicDVukovicNVentricular and vascular remodelling – effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patientsJ Int Med Res200533Suppl 139A49A
   PubMed Web of Science ®Google Scholar
• DunselmanPHJMthe replacement of angiotensin converting enzyme inhibition (REPLACE) investigatorsEffects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failureInt J Cardiol20017713113811182175
   PubMed Web of Science ®Google Scholar
• HealeyJSBaranchukACrystalEPrevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysisJ Am Coll Cardiol2005451832183915936615
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol20054571271915734615
   PubMed Web of Science ®Google Scholar
• MadridAHBuenoMGRebolloJMUse of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized studyCirculation200210633133612119249
   PubMed Web of Science ®Google Scholar
• GalzeranoDCaselliSBreglioRA multicentre, randomized study comparing efficacy of telmisartan versus carvedilol in preventing atrial fibrillation recurrence in hypertensive patientsCirculation2007116Suppl II556557
   Google Scholar
• ChrysantSGPossible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidenceJ Hum Hypertens20051992393116049519
   PubMed Web of Science ®Google Scholar
• DaiWJFunkAHerdegenTBlockade of central angiotensin AT(1) receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in ratsStroke1999302391239810548676
   PubMed Web of Science ®Google Scholar
• GohlkePWeissSJansenAAT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious ratsJ Pharmacol Exp Ther2001298627011408526
   PubMed Web of Science ®Google Scholar
• XuJCulmanJBlumeATreatment with telmisartan and lithium of stroke-prone spontaneously hypertensive rats: survival studyNaunyn Schmiedebergs Arch Pharmacol2002365Suppl 1R67
   PubMedGoogle Scholar
• VincentJMKwanYWLungCSConstrictor and dilator effects of angiotensin II on cerebral arteriolesStroke2005362691269516269635
   PubMed Web of Science ®Google Scholar
• DupuisFAtkinsonJLiminanaPComparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive ratsJ Hypertens2005231061106615834293
   PubMedGoogle Scholar
• FogariRMugelliniAZoppiAEffect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patientsJ Hum Hypertens20062017718516306998
   PubMed Web of Science ®Google Scholar
• TRANSCEND® InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet20083721174118318757085
   PubMed Web of Science ®Google Scholar
• DienerHCSaccoRYusufSRationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: The Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS®)Cerebrovasc Dis20072336838017337887
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med20083591225123718753639
   PubMed Web of Science ®Google Scholar